Lupin shines on arm receiving USFDA approval for SUPRAX (Cefixime) Capsules

Lupin is currently trading at Rs. 534.65, up by 1.60 points or 0.30% from its previous closing of Rs. 533.05 on the BSE.

The scrip opened at Rs. 533.65 and has touched a high and low of Rs. 540.00 and Rs. 527.35 respectively. So far 15,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 574.05 on 17-Apr-2012 and a 52 week low of Rs. 409.50 on 14-Dec-2011.

Last one week high and low of the scrip stood at Rs. 545.00 and Rs. 523.15 respectively. The current market cap of the company is Rs. 23,878.00 crore.

The promoters holding in the company stood at 46.93% while Institutions and Non-Institutions held 44.05% and 9.02% respectively.

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc (collectively, Lupin) has received an approval for SUPRAX (Cefixime) Capsules 400 mg from the United States Food and Drugs Administration (USFDA). The company is also expecting to commence shipping of the product in the near future. 

The approval will expand Lupin’s range of SUPRAX dosage forms available to treat the approved indications in appropriate patients. Currently, SUPRAX is available as 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets.  

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.